Hydroxyurea exerts an anti-proliferative effect on T cells but has no direct impact on cellular activation

被引：12
作者：
Benito, J. M. [1 ]
Lopez, M. [1 ]
Lozano, S. [1 ]
Ballesteros, C. [1 ]
Gonzalez-Lahoz, J. [1 ]
Soriano, V. [1 ]
机构：
[1] Hosp Carlos III, Infect Dis Serv, Dept Infect Dis, Madrid 28029, Spain
来源：
CLINICAL AND EXPERIMENTAL IMMUNOLOGY | 2007年 / 149卷 / 01期
关键词：
HIV; hydroxyurea; T cell activation; T cell proliferation;
D O I：
10.1111/j.1365-2249.2007.03412.x
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Hydroxyurea (HU) is a cytostatic drug which has been used as an anti-HIV agent due mainly to its synergistic activity when combined with certain anti-retrovirals. In addition, HU might have a beneficial effect on parameters involved in the pathogenesis of HIV infection, such as immune activation. To test this hypothesis, the effect of HU on T cell proliferation and T cell activation, as well as the potential association between these two phenomena, were examined in an in vitro model. HU exerted a dose-dependent anti-proliferative effect on T cells, and modulated the expression of different activation markers. In cells exposed to HU, expression of CD25 and CD38 diminished in a dose-dependent manner, whereas expression of CD69 increased. However, when the expression of these markers was examined separately on proliferating and non-proliferating lymphocytes, HU did not exert any significant effect. Thus, the effect of HU on T cell activation is not direct and seems to be mediated through its effect on T cell proliferation.
引用
收藏
页码：171 / 177
页数：7
相关论文
共 28 条
[11]  
Gougeon ML, 1996, J IMMUNOL, V156, P3509
[12]   T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy [J].
Hunt, PW ;
Martin, JN ;
Sinclair, E ;
Bredt, B ;
Hagos, E ;
Lampiris, H ;
Deeks, SG .
JOURNAL OF INFECTIOUS DISEASES, 2003, 187 (10) :1534-1543
[13]   Hydroxyurea and HIV: 5 years later - from antiviral to immune-modulating effects [J].
Leri, F .
AIDS, 1999, 13 (12) :1433-1442
[14]   Enhanced HIV-specific immune responses in chronically HIV-infected patients receiving didanosine plus hydroxyurea [J].
López, M ;
Benito, JEM ;
Lozano, S ;
Barreiro, P ;
Martínez, P ;
González-Lahoz, J ;
Soriano, V .
AIDS, 2004, 18 (09) :1251-1261
[15]   Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters [J].
Lori, F ;
Rosenberg, E ;
Lieberman, J ;
Foli, A ;
Maserati, R ;
Seminari, E ;
Alberici, F ;
Walker, B ;
Lisziewicz, J .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1999, 15 (15) :1333-1338
[16]   Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanisms [J].
Lori, F ;
Foli, A ;
Groff, A ;
Luca, L ;
Whitman, L ;
Bakare, N ;
Pollard, RB ;
Lisziewicza, J .
AIDS, 2005, 19 (11) :1173-1181
[17]   Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir) [J].
Lori, F ;
Jessen, H ;
Lieberman, J ;
Clerici, M ;
Tinelli, C ;
Lisziewicz, J .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1999, 15 (07) :619-624
[18]   Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance [J].
Lori, F ;
Malykh, AG ;
Foli, A ;
Maserati, R ;
DeAntoni, A ;
Minoli, L ;
Padrini, DA ;
DegliAntoni, A ;
Barchi, E ;
Jessen, H ;
Wainberg, MA ;
Gallo, RC ;
Lisziewicz, J .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1997, 13 (16) :1403-1409
[19]   Long-term suppression of HIV-1 by hydroxyurea and didanosine [J].
Lori, F ;
Jessen, H ;
Foli, A ;
Lisziewicz, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (18) :1437-1438
[20]   HYDROXYUREA AS AN INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS-TYPE-1 REPLICATION [J].
LORI, F ;
MALYKH, A ;
CARA, A ;
SUN, D ;
WEINSTEIN, JN ;
LISZIEWICZ, J ;
GALLO, RC .
SCIENCE, 1994, 266 (5186) :801-805
123